Drug Trial Radar · NCT06895928
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Mar 28, 2025
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
SHR-A2102Drug
SHR-A2102 for injection.
Bevacizumab InjectionDrug
Bevacizumab injection.
Adebelimab InjectionDrug
Adebelimab injection.
Ametinib Mesylate TabletsDrug
Ametinib mesylate tablets.
Osimertinib Mesylate TabletsDrug
Osimertinib mesylate tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: From day 1 to 90 days after the last dose.
- Serious adverse events (SAEs)Time frame: From day 1 to 90 days after the last dose.
- Objective response rate (ORR)Time frame: About 2 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanxi Cancer hospital
Taiyuan, Shanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.